

Cervical Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C9F7610A76F4EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: C9F7610A76F4EN

Abstracts

The 7 major cervical cancer markets reached a value of US\$ 405.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 583.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.36% during 2024-2034.

The cervical cancer market has been comprehensively analyzed in IMARC's new report titled "Cervical Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical cancer refers to a type of cancer that originates in the cells of the cervix, which is the lower, narrow end of the uterus that connects to the upper vaginal opening. It primarily affects women, but in rare cases, it can also occur in individuals with a cervix who were assigned male at birth. Cervical cancer may not cause noticeable symptoms in its early stages. However, as the disease progresses, various indications associated with the ailment may include abnormal vaginal bleeding (post menopause, between periods, or after sexual intercourse), unusual vaginal discharge, pelvic pain, pain during urination, fatigue, unexplained weight loss, etc. The diagnosis of cervical cancer typically involves a combination of screening tests, clinical examinations, and diagnostic procedures. Numerous screening tests, such as pap smears or human papillomavirus (HPV) testing, are used to detect cellular anomalies or the presence of high-risk HPV types. If abnormalities are found, further diagnostic procedures like colposcopy (visual examination of the cervix), biopsy (sample collection for laboratory analysis), or imaging tests may be performed to confirm the diagnosis of cervical cancer or determine its extent and stage.

The escalating cases of human papillomavirus (HPV) infection, which can cause changes in the cellular structure and DNA, thereby leading to the development of precancerous lesions, are primarily driving the cervical cancer market. Additionally, the

rising prevalence of various associated risk factors, including engaging in sexual activity at an early age, weakened immune system, long-term use of oral contraceptives, multiple sexual partners, a history of sexually transmitted infections (STIs), etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which block certain proteins in cancer cells, allowing the immune system to recognize and destroy cancer cells more effectively, is further bolstering the market growth. Apart from this, the inflating application of adaptive radiation therapy, since it allows for precise radiation delivery, thereby minimizing damage to healthy tissue while maximizing tumor control, is acting as another significant growth-inducing factor. Additionally, the shifting preferences from conventional pap smears towards liquid-based cytology on account of its several associated benefits, including better cell preservation and reduced specimen variability, are expected to drive the cervical cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cervical cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cervical cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical cancer market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cervical cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cervical cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cervical cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Cervical Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-203...

Market Insights

How has the cervical cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cervical cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cervical cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of cervical cancer across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of cervical cancer by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of cervical cancer by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with cervical cancer across the seven major markets?

What is the size of the cervical cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cervical cancer?

What will be the growth rate of patients across the seven major markets?

Cervical Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cervical cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cervical cancer market?

What are the key regulatory events related to the cervical cancer market?

What is the structure of clinical trial landscape by status related to the cervical cancer market?

What is the structure of clinical trial landscape by phase related to the cervical cancer market?

What is the structure of clinical trial landscape by route of administration related to the cervical cancer market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CERVICAL CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CERVICAL CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CERVICAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (?2018-2034?)

7.2.4 Epidemiology by Gender (?2018-2034?)

7.2.5 Diagnosed Cases (?2018-2034?)

7.2.6 Patient Pool/Treated Cases (?2018-2034?)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (?2018-2034?)

7.3.4 Epidemiology by Gender (?2018-2034?)

7.3.5 Diagnosed Cases (?2018-2034?)

7.3.6 Patient Pool/Treated Cases (?2018-2034?)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (?2018-2034?)

7.4.4 Epidemiology by Gender (?2018-2034?)

7.4.5 Diagnosed Cases (?2018-2034?)

7.4.6 Patient Pool/Treated Cases (?2018-2034?)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (?2018-2034?)

7.5.4 Epidemiology by Gender (?2018-2034?)

7.5.5 Diagnosed Cases (?2018-2034?)

7.5.6 Patient Pool/Treated Cases (?2018-2034?)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (?2018-2034?)

7.6.4 Epidemiology by Gender (?2018-2034?)

7.6.5 Diagnosed Cases (?2018-2034?)

7.6.6 Patient Pool/Treated Cases (?2018-2034?)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 CERVICAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CERVICAL CANCER - UNMET NEEDS

10 CERVICAL CANCER - KEY ENDPOINTS OF TREATMENT

11 CERVICAL CANCER - MARKETING PRODUCTS

- 11.1 List of Cervical Cancer Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) - Merck & Co.
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Keytruda (Pembrolizumab) - Merck & Co

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Tivdak (Tisotumab Vedotin-Tftv) - Seagen Inc
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Avastin (Bevacizumab) - Genentech
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Hycamtin (Topotecan) - Novartis
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CERVICAL CANCER - PIPELINE DRUGS

- 12.1 List of Cervical Cancer Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Cemiplimab - Regeneron Pharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Tiragolumab - Hoffmann-La Roche
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results

- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 AGEN2034 - Agenus Inc.
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Tuksya - Merck and Co
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 LN-145 - Iovance Biotherapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CERVICAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CERVICAL CANCER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 CERVICAL CANCER - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Cervical Cancer - Market Size
 - 15.2.1.1 Market Size (2018-2023)

- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Cervical Cancer - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Cervical Cancer - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Cervical Cancer - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Cervical Cancer - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Cervical Cancer - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Cervical Cancer - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Cervical Cancer - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Cervical Cancer - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Cervical Cancer - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Cervical Cancer - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Cervical Cancer - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Cervical Cancer - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Cervical Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Cervical Cancer - Market Size
 - 15.7.1.1 Market Size (2018-2023)

- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Cervical Cancer - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Cervical Cancer - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Cervical Cancer - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Cervical Cancer - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Cervical Cancer - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Cervical Cancer - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Cervical Cancer - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Cervical Cancer - Access and Reimbursement Overview

16 CERVICAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CERVICAL CANCER MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CERVICAL CANCER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Cervical Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C9F7610A76F4EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9F7610A76F4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

